Preparation and characterization of a fully human monoclonal antibody specific for human tumor necrosis factor alpha

References

• Consani Fernandez SA, Diaz Cuna CL, Fernandez Rey L, et al. Infections in systemic autoimmune diseases. Reumatol Clin. 2020. DOI:10.1016/j.reuma.2020.06.009
   PubMed Web of Science ®Google Scholar
• Jacques P, Elewaut D. Tumor necrosis factor alpha-induced proteins: natural brakes on inflammation. Arthritis Rheum. 2012;64(12):3831–3834.
   PubMed Web of Science ®Google Scholar
• Wang Z, Song K, Zhao W, et al. Dendritic cells in tumor microenvironment promoted the neuropathic pain via paracrine inflammatory and growth factors. Bioengineered. 2020;11(1):661–678.
   PubMed Web of Science ®Google Scholar
• Alldred A. Etanercept in rheumatoid arthritis. Expert Opin Pharmacother. 2001;2(7):1137–1148.
   PubMedGoogle Scholar
• Davis JC, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67(3):346.
   PubMed Web of Science ®Google Scholar
• Jarvis B, Faulds D. Etanercept. Drugs. 1999;57(6):945–966.
   PubMed Web of Science ®Google Scholar
• Marotte H, Cimaz R. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014;14(5):569–572.
   PubMed Web of Science ®Google Scholar
• Blair Jarvis, Faulds D, Faulds D. Etanercept. Drugs. 1999;57(6):945–966.
   PubMed Web of Science ®Google Scholar
• Ferraccioli GF, Di Poi E. Etanercept in rheumatoid arthritis. N Engl J Med. 1999;340:2000–2001.
   PubMed Web of Science ®Google Scholar
• Brankov N, Jacob SE. Adalimumab. Journal of the Dermatology Nurses’ Association. 2016;8(3):216–220.
   Web of Science ®Google Scholar
• Burness CB, Deeks ED, Burness CB, et al. Adalimumab. Drugs. 2012;72(18):2385–2395.
   PubMed Web of Science ®Google Scholar
• Hebeisen M, Scherer A, Micheroli R, et al. Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. PLoS One. 2019;14(5):e0216746.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62(90002):13–16.
   Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial (vol 48, pg 35, 2003). Arthritis Rheumatism. 2003;48(1):855.
   Web of Science ®Google Scholar
• Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010;62(4):917–928.
   PubMed Web of Science ®Google Scholar
• Oldfield V, Plosker GL. Golimumab. Biodrugs. 2009;23(2):125–135.
   PubMed Web of Science ®Google Scholar
• Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010;2(4):428–439.
   PubMed Web of Science ®Google Scholar
• Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49(9):1056–1070.
   PubMed Web of Science ®Google Scholar
• Duggan ST, Keam SJ. Certolizumab Pegol. Biodrugs. 2009;23(6):407–417.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Warren RB, Gottlieb AB, et al. Long-Term efficacy of certolizumab pegol for the treatment of plaque psoriasis: three-year results from two randomised phase 3 trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2020. DOI:10.1111/bjd.19393.
   Google Scholar
• Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013;12(7):703–708.
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131(2):308–316.
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–172.
   PubMed Web of Science ®Google Scholar
• Chen C, Liang H, Liao X, et al. A humanized chimeric antibody Hai178 targeted to the beta subunit of F1F0 ATP synthase. Tumour Biol. 2016;37(12):15903–15912.
   Google Scholar
• Liao MML, Sunstrom N-A. A transient expression vector for recombinant protein production in Chinese hamster ovary cells. J Chem Technol Biot. 2006;81(1):82–88.
   Web of Science ®Google Scholar
• Ishihara T, Nakajima N, Kadoya T. Evaluation of new affinity chromatography resins for polyclonal, oligoclonal and monoclonal antibody pharmaceuticals. J Chromatogr B. 2010;878(23):2141–2144.
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Chumsae C, et al. Characterization of lower molecular weight artifact bands of recombinant monoclonal IgG1 antibodies on non-reducing SDS-PAGE. Biotechnol Lett. 2007;29(11):1611–1622.
   PubMed Web of Science ®Google Scholar
• Pham V, Tropea J, Wong S, et al. High-Throughput Protein Sequencing. Anal Chem. 2003;75(4):875–882.
   PubMed Web of Science ®Google Scholar
• Goyon A, Excoffier M, Janin-Bussat M-C, et al. Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies. J Chromatogr B. 2017;1065-1066:119–128.
   PubMed Web of Science ®Google Scholar
• Ho D, Fletcher T, Ni JHT. Kinetic analysis of antibodies from different cultured media. Biopharm International. 2013;26:48–51,5.
   Web of Science ®Google Scholar
• Ji X, Lu W, Zhou H, et al. Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity. Appl Microbiol Biotechnol. 2013;97(19):8547–8558.
   PubMed Web of Science ®Google Scholar
• Wu D, Cederbaum A. Cytochrome P4502E1 sensitizes to tumor necrosis factor alpha-induced liver injury through activation of mitogen-activated protein kinases in mice. HEPATOLOGY. 2008;47(3):1005–1017.
   PubMed Web of Science ®Google Scholar
• Tang W, Lu Y, Tian QY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332(6028):478–484.
   PubMed Web of Science ®Google Scholar
• Thwin MM, Douni E, Aidinis V, et al. Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res Ther. 2004;6(3):R282–94.
   PubMed Web of Science ®Google Scholar
• Mabika M, Laburn H. The role of tumour necrosis factor-alpha (TNF-α) in fever and the acute phase reaction in rabbits. Pflügers Archiv. 1999;438(2):218–223.
   PubMed Web of Science ®Google Scholar
• Song M-Y, Park S-K, Kim CS, et al. Characterization of a novel anti-human TNF- alpha murine monoclonal antibody with high binding affinity and neutralizing activity. Exp Mol Med. 2008;40(1):35–42.
   PubMed Web of Science ®Google Scholar
• Pizanis A, Mutschler W, Rose S. Monoclonal antibody to tumor necrosis factor-α modulates hepatocellular Ca2+ homeostasis during hemorrhagic shock in the rat. J Mol Med. 1999;77(1):8–13.
   PubMed Web of Science ®Google Scholar
• Yang Y-L, Li J-P, Xu X-P, et al. Protective effects of tumor necrosis factor α antibody and ulinastatin on liver ischemic reperfusion in rats. World J Gastroenterol. 2004;10(21):3161–3164.
   PubMed Web of Science ®Google Scholar
• Watanabe M. Characteristics of TNFα- and TNFβ-Induced fever in the rabbit. Jpn J Physiol. 1992;42(1):101–116.
   PubMedGoogle Scholar
• Resemann A, Jabs W, Wiechmann A, et al. Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencing. MAbs. 2016;8(2):318–330.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Becciolini A, Carletto A, et al. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. Rheumatol Int. 2020;40(2):263–272.
   PubMed Web of Science ®Google Scholar
• Shuwa HA, Dallatu MK, Yeldu MH, et al. Effects of Adalimumab, an anti-tumour necrosis factor-Alpha (TNF-alpha) antibody, on obese diabetic rats. Malays J Med Sci. 2018;25:51–62.
   PubMed Web of Science ®Google Scholar